Advertisement

The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report

  • Lynn A. Farrugia
  • Sean H. Rhyee
  • Sharan L. Campleman
  • Bryan Judge
  • Louise Kao
  • Anthony Pizon
  • Lauren Porter
  • Anne M. Riederer
  • Timothy Wiegand
  • Diane Calello
  • Paul M. Wax
  • Jeffrey Brent
  • On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group
Original Article

Abstract

The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients. Adults aged 19–65 were the most commonly reported age group. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen again the most common agent reported. There were 93 fatalities reported in 2017. Treatment interventions were frequently reported with 30.6% receiving specific antidotal therapy. Major trends in demographics and exposure characteristics remained similar to past years’ reports. While treatment interventions were commonly required, fatalities were rare.

Keywords

Poisonings Overdose Surveillance Epidemiology Medical toxicology 

Notes

Acknowledgments

Toxicology Investigators Consortium (ToxIC) Study Group Collaborators:

Algren DA, Alwasiyah D, Beauchamp GA, Bentur Y, Berman AJ, Beuhler MC, Biary R, Bonney C, Boyle KL, Bruccoleri RC, Burns MM, Cahana A, Cannon RD, Caravati EM, Carey J, Chiba T, Christian M, Cook MD, Cumpston K, Davis A, Dribben W, Eisenga BH, Eldos Y, Falkowitz DM, Farkas A, Finkelstein Y, Fisher E, Froberg BA, Ganetsky M, Garlich F, Geib AJ, Gittinger M, Gorodetsky R, Greene SC, Hart K, Hendrickson RG, Hernandez S, Hodgman M, Hoyte C, Judge BS, Kao L, Katz KD, Kessler BD, King JD, Kirschner RI, Kostic M, Leikin JB, Levine M, Lowry JA, Lurie Y, Majlesi N, Malashock H, Manini AF, Marino R, McKay CA Jr., McKeever R, McKeown N, Meadors K, Moore E, Morgan B, Mullins ME, Nacca NE, Niruntarai S, Nogar JN, Olmedo R, Othong R, Riley BD, Rusyniak DE, Schimmel J, Schult R, Schwarz ES, Scoccimarro A, Seifert SA, Shafer S, Smith S, Smolinske SC, Spyres M, Steck A, Stripp M, Sullivan R, Theobald J, Troendle M, Vearrier, Warrick BJ, Watts D, Wills B, Zosel AE.

We also wish to thank study coordinators AB Adefeso, D Hopkins, Julie Licata, Tammy Phan, Andrea Ramirez, Mellissa VandenBerg, and Love Wilson.

Funding Sources

This study received funding from the NIH National Institute on Drug Abuse, 1R56DA38366 and 1R01DA037317-01, a data sharing contract with the US Food and Drug Administration and BTG International Inc. (North America).

Compliance with Ethical Standards

Conflicts of Interest

None

Previous Presentation of Data

None

Supplementary material

13181_2018_679_MOESM1_ESM.docx (32 kb)
ESM 1 (DOCX 32 kb)

References

  1. 1.
    Wax PM, Kleinschmidt KC, Brent J. ACMT ToxIC Case Registry Investigators. The Toxicology Investigators Consortium (ToxIC) Registry. J Med Toxicol. 2011;7(4):259–65.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Brent J, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry—the 2010 experience. J Med Toxicol. 2011;7(4):266–76.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wiegand TJ, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry—the 2011 experience. J Med Toxicol. 2012;8(4):360–77.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wiegand T, Wax P, Smith E, Hart K, Brent J. The Toxicology Investigators Consortium Case Registry—the 2012 experience. J Med Toxicol. 2013;9(4):380–404.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rhyee SH, Farrugia L, Wiegand T, et al. The Toxicology Investigators Consortium Case Registry—the 2013 experience. J Med Toxicol. 2014;10(4):342–59.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rhyee SH, Farrugia L, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry—the 2014 experience. J Med Toxicol. 2015;11(4):388–409.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Farrugia L, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry—the 2015 experience. J Med Toxicol. 2016;12(3):224–47.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Farrugia L, Rhyee SH, Calello DP, et al. The Toxicology Investigators Consortium Case Registry—the 2016 experience. J Med Toxicol. 2017;13(3):203–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th annual report. Clin Toxicol (Phila). 2017;55(10):1072–252.CrossRefGoogle Scholar
  10. 10.
    Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL. 2015 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd annual report. Clin Toxicol (Phila). 2016;54(10):924–1109.CrossRefPubMedGoogle Scholar
  11. 11.
    Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol (Phila). 2015;53(10):962–1146.CrossRefGoogle Scholar
  12. 12.
    Center for Behavioral Health Statistics and Quality. 2016 national survey on drug use and health: detailed tables. Substance Abuse and Mental Health Services Administration, Rockville, MD 2017.Google Scholar
  13. 13.
    Ouellette L, Cearley M, Judge B, Riley B, Jones J. Cooking with cannabis: the rapid spread of (mis)information on YouTube. Am J Emerg Med 2017.Google Scholar
  14. 14.
    Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatr. 2017;190:142–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Vo KT, Horng H, Li K, Ho RY, Wu AHB, Lynch KL, et al. Cannabis intoxication case series: the dangers of edibles containing tetrahydrocannabinol. Ann Emerg Med. 2018;71:306–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Sierzant C, Judge B. Cooking with cannabis: severe toxicity following the use of cannabutter. Clin Toxicol. 2016;54:708.Google Scholar
  17. 17.
    FDA (U.S. Food and Drug Administration). 2011. Neurontin® (gabapentin) capsules, Neurontin® (gabapentin) tablets, Neurontin® (gabapentin) oral solution. NDA 020235/S-036; NDA 020882/S-022; NDA 021129/S-022 FDA Approved Labeling Text dated 03/01/2011. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s036,020882s022,021129s022lbl.pdf; accessed 12 Feb 2018.
  18. 18.
    FDA. 2012. Highlights of prescribing information: Lyrica (pregabalin) capsules, CV Lyrica (pregabalin) oral solution, CV. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021446s028lbl.pdf; accessed 12 Feb 2018.
  19. 19.
    Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ database. CNS Drugs. 2016;30(7):647–54.CrossRefPubMedGoogle Scholar
  20. 20.
    Office for National Statistics [United Kingdom]. 2017. Death related to drug poisoning in England and Wales from 1993 onwards, by cause of death, sex, age and substances involved in the death. Latest release: Deaths related to drug poisoning in England and Wales: 2016 registrations, Released: 2 Aug 2017. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2016registrations; accessed 12 Feb 2018.
  21. 21.
    Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(9):1083–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th annual report. Clin Toxicol (Phila). 2012;50(10):911–1164.CrossRefGoogle Scholar
  23. 23.
    Goodman CW, Brett AS. Gabapentin and Pregabalin for pain—is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411–4.  https://doi.org/10.1056/NEJMp1704633.CrossRefPubMedGoogle Scholar
  24. 24.
    Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry. 2015;172(5):487–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© American College of Medical Toxicology 2018

Authors and Affiliations

  • Lynn A. Farrugia
    • 1
  • Sean H. Rhyee
    • 2
  • Sharan L. Campleman
    • 3
  • Bryan Judge
    • 4
  • Louise Kao
    • 5
  • Anthony Pizon
    • 6
  • Lauren Porter
    • 7
  • Anne M. Riederer
    • 3
  • Timothy Wiegand
    • 8
  • Diane Calello
    • 9
  • Paul M. Wax
    • 10
  • Jeffrey Brent
    • 11
  • On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group
  1. 1.Hartford Hospital and University of Connecticut School of MedicineHartfordUSA
  2. 2.University of Massachusetts Medical SchoolWorcesterUSA
  3. 3.American College of Medical ToxicologPhoenixUSA
  4. 4.Spectrum Health Blodgett HospitalGrand RapidsUSA
  5. 5.Indiana University School of MedicineIndianapolisUSA
  6. 6.University of Pittsburgh School of Medicine and University of Pittsburgh Medical CenterPittsburghUSA
  7. 7.Banner-University Medical Center PhoenixPhoenixUSA
  8. 8.University of Rochester Medical Center and Strong Memorial HospitalRochesterUSA
  9. 9.New Jersey Medical SchoolRutgers, The State University of New JerseyNewarkUSA
  10. 10.University of Texas Southwestern Medical SchoolDallasUSA
  11. 11.University of Colorado School of MedicineAuroraUSA

Personalised recommendations